SPAC for 2025 BLA: Non-vi­ral gene ther­a­py biotech en­Gene, steered by ex-Myth­ic lead­ers, finds For­bion blank check

Near­ing a Phase II for its non-vi­ral gene ther­a­py, a small Cana­di­an biotech plans to com­bine with a For­bion-led blank check com­pa­ny to land a seat on Nas­daq and get to an FDA ap­proval re­quest in the first half of 2025.

With the help of ad­di­tion­al back­ers like Omega Funds, Cowen Health­care In­vest­ments, BVF Part­ners and oth­ers, en­Gene will snag about $135 mil­lion in cap­i­tal from its pro­posed mar­riage with For­bion Eu­ro­pean Ac­qui­si­tion Corp. The SPAC, formed by the Dutch VC fund just as blank checks were go­ing out of vogue, went through a $110 mil­lion IPO in De­cem­ber 2021. It had about $111 mil­lion in its trust at the end of March.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN